MiMedx (NSDQ:MDXG) said it inked a distribution deal with Medtronic (NYSE:MDT) for its Purion allograft line.
The deal calls for the Purion allografts to be private-labeled by Medtronic’s SpinalGraft Technologies subsidiary, according to a press release.
MiMedx acquired the Purion technology when it bought Surgical Biologics in 2011. The technology processes human amniotic membrane into allografts used to heal surgical wounds and prevent adhesion. The Purion line includes the AmnioFix, AmnioFix Sports Med, AmnioFix Injectable, AmnioFix Wrap, EpiFix and EpiFix Micro allografts.
"This agreement is a significant milestone for MiMedx in expanding our customer base and broadening the breadth of physicians and patients with access to our Purion processed allografts. By partnering with Medtronic, many additional physicians and patients can be served through the extensive distribution arm and presence that Medtronic has in the spinal surgery market," MiMedx chairman & CEO Parker Petit said in prepared remarks.
"We are very excited about our relationship with Medtronic," added president & COO Bill Taylor. "Medtronic has done an extraordinary job in serving the needs of practicing physicians. With the growing demand for an offering that can deliver the outcomes achieved by our Purion processed allografts, it is critical to align with a partner that has unparalleled respect among physicians and extensive relationships in this sector of healthcare."